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Abstract
Introduction: Liquid chromatography coupled to atmospheric pressure ionization tandem mass spectrometry (LC-ESI-MS/MS) is currently conside-
red the reference method for quantitative determination of urinary free cortisol (UFC). One of the major drawbacks of this measurement is a particu-
lar form of matrix effect, conventionally known as ion suppression. 
Materials and methods: We describe here the case of a 66-year-old-patient referred to the daily service of general medicine for intravenous an-
tibiotic administration due to a generalized Staphylococcus aureus infection and for routine 24 hours UFC monitoring in the setting of glucocorticoid 
replacement therapy. 
Results: The observation of 10-fold decrease of internal standard of cortisol signal led us to hypothesize the presence of an ion suppression effect 
due to a co-eluting endogenous compound. Screening analysis of tandem mass spectrometry (MS/MS) spectra of the interfering molecule, along 
with in vitro confirmation analyses, were suggestive of the presence of high concentration of piperacillin. The problem was then easily solved with 
minor modifications of the chromatographic technique. 
Conclusions: According to our findings, antibiotic therapy with piperacillin/tazobactam should be regarded as an important interference in UFC 
assessment, which may potentially affect detection capability, precision and accuracy of this measurement. This case report emphasizes that accu-
rate anamnesis and standardization of all phases of urine collection are essential aspects for preventing potential interference in laboratory testing.
Key words: urinary free cortisol; ion suppression; pre-analytical phase; piperacillin; mass spectrometry
Received: June 20, 2017 Accepted: August 30, 2017
Urinary free cortisol assessment by liquid chromatography tandem mass 
spectrometry: a case study of ion suppression due to unacquainted 
administration of piperacillin
Elisa Danese*1, Gian Luca Salvagno1, Alessandra Guzzo1, Samuele Scurati2, Cristiano Fava3, Giuseppe Lippi1 
1Clinical Biochemistry section, Department of Neurological, Biomedical and Movement Sciences, University of Verona, Italy
2DASP s.r.l., Gerenzano, Italy
3Unit of General Medicine and Hypertension, Department of Medicine, University of Verona, Italy
*Corresponding author: elisa.danese@univr.it
Pre-analytical mysteries
Introduction
According to current guidelines, urinary free cor-
tisol (UFC) is one of the first-line biochemical test 
for screening endogenous Cushing syndrome 
(1). Due to its higher selectivity and specificity 
compared to conventional immunoassays, liquid 
chromatography - tandem mass spectrometry 
(LC-MS/MS) has become the reference technique 
for measuring UFC in clinical practice. Despite an 
incomparable selectivity, MS detection is not 
completely foolproof, especially when coupled 
with electrospray ionization (ESI) sources, the 
most widely used interfaces used for UFC assess-
ment. One of the most important factors impair-
ing the accurate performance of a LC-MS/MS 
technique is the ion suppression (IS)/enhance-
ment effect, an actual expression of a wider phe-
nomenon conventionally known as “matrix ef-
fect”. Ion suppression occurs when matrix com-
ponents co-eluting with compound/s of interest 
impair the efficiency of analyte ionization, thus 
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affecting detection capability, precision and ac-
curacy of measurements (2). 
Although many authors recently underscored 
the importance of understanding IS effect in 
clinical MS applications, only a limited number 
of validations of methods have been published 
to consistently address this issue. To date, stud-
ies reporting an evaluation of matrix effect in 
UFC assessment by LC-MS/MS failed to observe 
any IS in study samples (3,4). 
We report here for the first time a case study of IS 
due to high concentration of piperacillin in the 
urine sample. This paradigmatic case of biologi-
cal interference which may be prevented by an 
accurate collection of patient information prior 
to analysis, reinforces the concept that pre-ana-
lytical phase remains crucial for quality of the to-
tal testing process, even when using high perfor-
mance techniques such as LC-MS/MS (5-8). Since 
piperacillin is commonly used as a first-choice an-
tibiotic in combination with the beta-lactamase 
inhibitor tazobactam for treating moderate-to-
severe infections in critical patients, we describe 
here the analytical challenge of, and a valid ap-
proach to overcome, pre-analytical issues in 
measurement of UFC, which might be a rather 
frequent event in clinical practice (9). 
Laboratory analysis
Case description
We describe here the case of a 66-year-old fe-
male patient referred to the daily service of gen-
eral medicine of the University Hospital of Vero-
na (Italy), for intravenous antibiotic treatment of 
a generalized Staphylococcus aureus infection. 
The clinical history, based on a thoughtful anam-
nesis, revealed Addison disease occurred after 
surgical management of a Cushing’s syndrome. 
The patient also received hydrocortisone thera-
py for four years due to adrenal insufficiency. 
During routine assessment, 24-hours urine sam-
ples were collected for monitoring the glucocor-
ticoid replacement therapy (10). The 24 h urine 
samples were collected in a standard 24 h urine 
container, with no preservatives. Urine was then 
aliquoted and stored at - 20 °C until analysis. The 
method currently used for assessing UFC in our 
hospital laboratory was a competitive solid 
phase 125I radioimmunoassay (RIA; Cortisol RIA 
kit, Beckman Coulter, Brea, USA). The bound ra-
dioactivity was measured with COBRA II Gamma 
counter (Packard, Ramsey, USA). The results of 
UFC assessment with this method, along with 
other relevant laboratory tests ordered at the 
time of urine sample collection are shown in Ta-
ble 1. The study protocol was approved by the 
University Hospital of Verona Institutional Re-
view Board.
What happened?
Due to the extremely high UFC value, the urine 
sample was aliquoted immediately after analysis 
and then stored at - 20 °C. Aliquots (of 300 μL, 
each) were then used for validating the inter-as-
say variability of a new commercial CE-IVD LC-
MS/MS method, which had been recently intro-
duced in our laboratory for replacing the RIA 
technique. The assay was the MS urinary free 
cortisol/cortisone kit (ISBN-BSN, Castelleone, Ita-
ly), which requires single manual dilution, pro-
tein precipitation and contains a D4 isotope-la-
belled internal standard. The method was found 
Parameter Value Unit Reference value
C-reactive protein < 3 mg/L < 5
Haematocrit 0.36 L/L 0.35-0.47
Haemoglobin 116 g/L 120-150
Creatinine 158 μmol/L 44-106
eGFR (CKD-EPI) 29 mL/min/1.73m2 > 60
UFC
690 nmol/L
41.3-220.7
2484 nmol/24h
UFC - urinary free cortisol. eGFR - estimated glomerular 
filtration rate. CKD-EPI - Chronic Kidney Disease Epidemiology 
Collaboration.
Table 1. Routine clinical chemistry values
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to be linear up to 5000 nmol/l and is character-
ized by a limit of quantification (LOQ) of 6 
nmol/L. 
The LC-MS/MS analytical system was a Nexera 
X2 series UHPLC (Shimadzu, Kyoto, Japan) cou-
pled with a 4500 MD triple quadrupole MS de-
tector (Sciex, Milan, Italy). 
Compared to the other specimens tested in the 
same analytical run, the case study sample dis-
played a 10-fold lower signal (in terms of area 
under the peak) of internal standard (D4-Corti-
sol). Even the cortisol signal and the correspond-
ing quantitative UFC concentration were very 
low compared to those we would have expect-
ed from data obtained with RIA. The software in-
tegration allowed generating a predicted UFC 
concentration of 229 nmol/L. However, due to 
the high degree of IS, normalization of cortisol 
value by its internal standard was inherently in-
accurate and the following quantification was 
hence unreliable. A series of experiments were 
then carried out for confirming the presence of 
IS, understanding the source of the problem, 
and ultimately overcoming the possible interfer-
ence. 
Evaluation of IS
A post column infusion experiment was per-
formed for assessing IS. A urine sample with low 
cortisol concentration (i.e. 13 nmol/L) and the 
case-study urine sample were injected while a 
cortisol solution (1 μmol/L) in 80:20 mobile 
phase A:B was infused into the mass spectrome-
ter at a flow rate of 10 μL/min. As expected, a 
drop in the baseline signal occurring exactly in 
the elution time of cortisol was observed in the 
case sample but not in the other urine sample 
(Figure 1).
Figure 1. Post-column infusion experiment for evaluation of ion suppression affecting cortisol signal in a normal urine sample (A) 
and in the case-study sample (B). Black arrows indicate the elution time of cortisol. Vertical lines indicate the valve switch from the 
exhaust to the mass spectrometer. Cps - counts per second. 
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Identification of interfering compound
The profile of the interfering compound was 
studied with a hybrid triple quadrupole/linear 
ion trap mass spectrometer (QTRAP 5500, Sciex, 
Milan, Italy) interfaced with a Nexera X2 series 
UHPLC (Shimadzu, Kyoto, Japan). General screen-
ing of interference was made by using the full-
scan enhanced MS modality. Parent ions pre-
senting with signal threshold > 100,000 counts 
per second (cps) were automatically fragmented 
to obtain the corresponding full-scan MS/MS 
spectra. Among all acquired compounds, those 
with retention time close to that of cortisol were 
analysed against the Analyst software (Sciex, Mi-
lan, Italy) MS/MS spectra database to provide 
tentative identification of compound. A match 
was finally found, which allowed identifying 
piperacillin as the interfering substance.
Identity verification of interfering compound
With the aim of confirming piperacillin interfer-
ence, the LC-MS/MS method was modified by 
adding the multiple reaction monitoring (MRM) 
m/z transitions of piperacillin. The subsequent 
re-analysis of case-study sample showed the 
presence of all set up transitions for both cortisol 
and piperacillin, thus confirming the presence of 
this drug in the study sample. An audit with the 
clinicians revealed that the patient was currently 
taking intravenous piperacillin/tazobactam 
treatment (2.25 g every 6 hours). 
With the aim of reproducing this phenomenon 
in vitro, scalar dilutions of the drug (piperacillin/
tazobactam 4 g/0.5 g) were spiked into a urine 
sample (UFC: 110 nmol/L), to achieve final con-
centrations between 15.6-1000 μg/mL. Samples 
were then extracted according to the standard 
protocol and analysed with the modified meth-
od. As expected, the drug displayed an elution 
time very close to that of cortisol (Figure 2). 
Moreover, the sample spiked with a drug con-
centration of 1000 μg/mL displayed a signal for 
the second product very similar to that observed 
in the case-study sample (i.e., area of the m/z 
transition 518.2/160.1 of 20 and 17 million, re-
spectively). The signals from the first product ion 
(m/z transition 518.2/143.2) were saturated in-
stead in both samples.
As shown in Figure 3, the addition of piperacillin 
at final concentration of 1000 μg/mL in the urine 
sample induced an 80% signal decay compared 
to the sample without the spiked drug. By pro-
gressively diluting the piperacillin concentra-
tions, the signal of the internal standard linearly 
increased, until reaching a recovery of 80% at a 
final concentration of 15.6 μg/mL. 
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Figure 2. MRM chromatograms of cortisol and piperacillin. Representative chromatograms of a urine sample with UFC of 110 nmol/L 
spiked with piperacillin at a final concentration of 125 μg/mL. Cps - counts per second. XIC - Extracted ion chromatogram. MRM - 
multiple reaction monitoring. 
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Figure 4. Cortisol and D4-cortisol signals before (A) and after (B) method modification. Cps - counts per second.
Figure 3. D4-cortisol signal suppression according to piper-
acillin increasing concentrations. Starting from a standard so-
lution of 2000 μg/mL of piperacillin the follow scalar dilutions 
were spiked into an urine sample with UFC concentration of 
110 nmol/L (1:2, 1:4, 1:8, 1:16, 1:32 ,1:64). The curve was fitted 
by using a non-linear regression one-phase decay analysis and 
showed a correlation of 0.99. PIP – piperacillin.
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Solution
Strategy implemented to remove IS due to 
piperacillin interference
Among the many strategies available to eliminate 
or attenuate the matrix effect, we decided to im-
prove retention and separation of co-eluting com-
pound by re-optimizing the chromatographic 
conditions. As shown in Figure 4, the cortisol and 
the relative internal standard were found to be 
more retained by the C18 column after reducing 
the oven temperature from 60 °C to 30 °C. Conse-
quently, their signals had no more signs of IS. The 
concentration of UFC could hence be calculated as 
130 nmol/L after this minor modification.
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Discussion
Ion suppression is one of the most important 
challenges in MS analysis, so that is has been de-
fined as the Achilles’ heel of quantitative LC–ESI-
MS/MS analysis (11). This case report describes 
an IS effect attributable to piperacillin, seriously 
impairing the accurate assessment of UFC de-
spite the use of an isotope labelled internal 
standard (which is usually enough to correct for 
the matrix effect). The initial quantification led to 
overestimating the real concentration of approx-
imately 80% due to reduced detection capabili-
ty of decreased UFC and internal standard sig-
nals. Notably, an even higher overestimation 
was noticed using the RIA, which was probably 
due to additional interference with this assay. 
Although we did not performed a real quantifi-
cation of the drug in the 24 hours urine sample, 
it is reasonable to assume, by comparing ex vivo 
and in vitro data, that 50-60% of the drug accu-
mulated unmodified in urine (i.e. about 1 g/L) 
during the 24 hours collection. By assuming the 
most widely accepted linear pharmacokinetics 
profile and renal clearance of piperacillin, we can 
hence speculate that a IS effect caused by this 
drug might affect the UFC quantification, thus 
generating a signal reduction of up to 80% dur-
ing infusion treatment, and up to 20% five hours 
after the last administration (12). To exclude this 
important pre-analytical interference, urine sam-
ple collection for UFC assessment should hence 
be started the day after the end of i.v. infusions. 
Even more importantly, accurate information 
about the pharmacological treatment should be 
collected and sent to the laboratory along with 
sample and prescription. Therefore, this case re-
port further emphasizes the importance of a 
thoughtful collaboration between the clinics 
and the laboratory for identifying possible pre-
analytical source of interference and preventing 
diagnostic errors.
The improvement of methods using internal 
standards seems also mandatory to identify this 
potential challenge, especially when measuring 
isolate samples. By normalizing analyte response 
signal, the internal standard may also serve to 
compensate for IS, thus overcoming biological 
interference. However, when the IS is so severe 
to jeopardize the correct identification of signals 
from both analyte and internal standard (as in 
this case), many strategies exist to overcome or 
reduce the problem, some of which may also be 
relatively simply as those herein described 
(13,14).
What YOU should/can do in your 
laboratory to prevent such errors
•	 Accurate assessment of urinary free cortisol by 
LC-MS/MS can be impaired by antibiotic thera-
py with piperacillin/tazobactam.
•	 Matrix effect caused by the co-eluting drug can 
be recognized by implementing methods with 
isotope-labeled internal standard.
•	 Potential interferences can be prevented by 
knowing patient’s pharmacological treatment.
•	 By knowing pharmacokinetics of interfering 
drugs a correct timing for urine sample collec-
tion can be planned.
•	 Once recognized, matrix effects can be re-
solved by re-optimizing the chromatographic 
conditions.
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